Treatment of HPV Infection in Perimenopausal and Postmenopausal Women

• Status: Not yet recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

A randomized controlled study was conducted to determine the effects of vaginal estrogen and human interferon alpha 2b vaginal effervescent capsules on vaginal microecology in perimenopausal and postmenopausal women. To determine whether there is a synergistic effect between the two in the treatment of HPV infection in perimenopausal and postmenopausal women. To observe the effects of two drugs alone and combined on the vaginal immune environment of patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qianfoshan Hospital
• Treatments: Interferon alpha-2; Interferon-alpha; Interferons

Criteria

Inclusion Criteria:

• The age of 45-65 years (inclusive);

• HPV test indicates positive cervical and vaginal high-risk HPV;

• Cervical HSIL was excluded according to the 2015 US Transitional Clinical Guidelines for Cervical Cancer Screening.

• Patients with high-grade cervical intraepithelial lesions, who have undergone cervical conotomy or have undergone total or subtotal hysterectomy in the past, and HPV tests indicate high-risk cervical and vaginal HPV infection;

• If the combination of clear vaginal inflammation, symptomatic treatment is needed, then the group test;

• If the patients were complicated with abnormal uterine bleeding or postmenstrual bleeding, the reproductive system tumor should be excluded and cured, and then the patients were re-enrolled.

⑦ Volunteer to participate in clinical studies and sign informed consent.

Exclusion Criteria:

• Allergic to human interferon alpha 2b vaginal effervescent capsules or prolestrene cream;

• Pregnant or lactating patients;

• Patients with abnormal vaginal bleeding without clear cause;

④Patients with cervical high-grade intraepithelial lesions, gynecological malignancies, serious heart, brain, kidney, immune, blood and other systems and psychiatric neuropsychological diseases;

⑤Patients with consciousness disorder and communication disorder can not cooperate with the experiment;

⑥ Patients considered unsuitable or refused to participate in this clinical trial.